Print

Gilead Sciences, Inc. (GILD) On A Roll Even Before Breakthrough Hepatitis C Drug's Effects  
2/5/2014 7:13:13 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Gilead Sciences announced financial gains for the fourth quarter and full year of 2013 on Tuesday, even though the Foster City company's latest blockbuster drug debuted just a month before the end of the year, signaling even more gains ahead.

Gilead announced fourth-quarter profits of $791.4 million, or 47 cents a share, on revenues of $3.12 billion, with net income gaining 3.8 percent and revenues jumping 21 percent from the same quarter a year ago. For the full year, Gilead posted gains from 2012 of 15 percent in revenues and 18.5 percent in profits to net income of $3.07 billion on revenues of $11.2 billion.

Help employers find you! Check out all the jobs and post your resume.

//-->